<DOC>
	<DOCNO>NCT02590653</DOCNO>
	<brief_summary>The primary goal • To assess effect atorvastatin patient treat since first 24-96 hour disease parameter global regional myocardial deformation infarcted area structural functional property artery day 7 , 12 , 24 , 36 48 week treatment ; The secondary goal . To evaluate effect treatment : - parameter global regional myocardial deformation intact area day 7 , 12 , 24 , 36 48 week treatment ; - parameter global regional myocardial deformation depend degree coronary blood flow restoration thrombolysis myocardial infarction ( TIMI ) - systolic diastolic leave ventricular function presence initial impairment , absence negative dynamic parameter case normal baseline value ; - clinical diagnostic criterion development progression heart failure ; - dynamic duration extent myocardial ischemia accord daily ECG monitoring day 7 , 12 , 24 , 36 48 week treatment ; - appearance new prognostically significant cardiac arrhythmia - pulse wave velocity - thickness intima-media complex ( IMT ) ; 200 patient plan include randomize , single-center , open , prospective , control clinical trial , enrollment hold Department `` Therapy '' Medical Institute Penza State University . Definition study group : The patient STEMI ( myocardial infarction ST-segment elevation ) include study - Group 1 STEMI - 100 patient receive atorvastatin 80 mg / day 48 week ; - Group 2 STEMI - 100 patient receive atorvastatin 20 mg / day 48 week Planned number patient : Pre-Screening - 300 subject ; screen randomization - 200 subject . Patients randomized random number generation include group 1 2 . All include patient standard basis therapy coronary artery disease , accord national recommendation .</brief_summary>
	<brief_title>Assessment Effects Atorvastatin Therapy Myocardial Deformation Characteristics , Patients With STEMI</brief_title>
	<detailed_description>1 . Hypotheses : 1 . Atorvastatin therapy directly result improve deformation characteristic hibernate myocardium due pleiotropic effect endothelial dysfunction atherosclerotic plaque stability , well stimulation angiogenesis ischemic zone myocardium . 2 . Long-term atorvastatin therapy improve morphofunctional property large artery decrease severity endothelial dysfunction patient history myocardial infarction . 3 . Atorvastatin cause anti-ischemic effect , use long time . 2.1 . Primary objective To evaluate effect atorvastatin , start 24 96 hour disease onset , parameter global regional myocardial deformation zone infarction , well morphofunctional property artery , Day 7 Weeks 12 , 24 , 36 48 treatment ; 2.2 . Secondary objective . To evaluate : - effect treatment parameter global regional myocardial deformation zone intact myocardium Day 7 Weeks 12 , 24 , 36 48 treatment ; - effect treatment parameter global regional myocardial deformation depend TIMI blood flow grade ; - effect treatment systolic diastolic function leave ventricle patient impaired leave ventricular function baseline , well ability treatment prevent deterioration leave ventricular function patient normal leave ventricular function baseline ; - effect treatment heart failure development progression assess use correspond clinical diagnostic criterion ; - effect treatment duration time course myocardial ischemia use 24 hour ECG monitoring Day 7 Weeks 12 , 24 , 36 48 treatment ; - effect treatment appearance new prognostically significant disorder cardiac rhythm ; - effect treatment pulse wave velocity cardio-ankle vascular index ( CAVI ) ; - effect treatment intima-media thickness ( IMT ) ; - effect treatment result automate quantitative vascular elasticity measurement , pulse wave pulse pressure ; - effect treatment endothelial function use reactive hyperemia test ; - effect treatment time course blood chemistry parameter ( i.e. , total cholesterol , HDL , LDL , triglyceride , creatinine , C-reactive protein ( CRP ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) creatinkinase ( CK ) ; - safety treatment ; - effect treatment patient 's well-being quality life ; - patient compliance therapy . 2.3 . Scientific novelty study It plan study , first time , effect long-term aggressive statin therapy functional status myocardium zone ischemia , lesion necrosis patient STEMI use two-dimensional strain procedure . It plan , first time , comprehensively study effect aggressive statin therapy status vasculature , measure multiple parameter characterize morphofunctional status elastic muscular artery patient document coronary heart disease ( CHD ) . 2.4 . Clinical significance study result . If propose hypothesis confirm primary endpoint describe Section 3 reach , new convince evidence support use long-term aggressive treatment Atorvastatin start early stage myocardial infarction obtain . Obviously , clinical benefit include improve prognosis decrease risk repeat vascular event . Favorable effect therapy morphofunctional status arterial vasculature play important role treatment patient . Positive result study form basis planning conduct large study pleiotropic effect Atorvastatin patient history myocardial infarction . 3 . Primary endpoint 1 . Statistically significant difference spatial velocity parameter myocardial deformation zone previous STEMI compare control . 2 . Statistically significant difference spatial velocity parameter myocardial deformation intact zone STEMI compare control . 3 . Statistically significant difference intima-media thickness ( IMT ) accord echo track data compare control . 4 . Statistically significant difference carotid-femoral pulse wave velocity CAVI compare control . 4 . Planning conduct study . It plan include 200 patient randomize , open-label , single-center , prospective , control clinical study ; patient recruit Department Therapy Penza State University Medical Institute . 4.1 . Allocation study group : Patients STEMI include study : Group 1 : 100 patient STEMI receive atorvastatin dose 80 mg per day 48 week ; Group 2 : 100 patient STEMI receive atorvastatin dose 20 mg per day 48 week . 4.2 . Planned number patient : Prescreening - 300 patient ; screen randomization - 200 patient . 4.3 . Study design . Patients randomize use sealed envelope number increase serial number 1 200 ; envelope contain information patient inclusion Group 1 Group 2 . Information treatment schedule dose regimen provide separately . 4.3.1 . Treatment regimen , dose titration strategy combination treatment principles Patients meet inclusion criterion meet exclusion criterion include study . Group A patient start treatment 24 96 hour onset STEMI : • Atorvastatin dose 80 mg per day . Group K patient start treatment 24 96 hour onset STEMI : • Atorvastatin dose 20 mg per day .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Signed Informed Consent Form 2 . Patients physical mental ability participate study 3 . Patients sex age 35 65 year 4 . Presence document STelevation myocardial infarction confirm ECG , well troponin I CKMB level . 5 . Presence hemodynamically relevant stenosis one artery ( i.e. , infarctrelated artery ) confirm coronary angiography ( CAG ) , occlusion artery exceed 30 % . 1 . A history repeat recurrent myocardial infarction ; 2 . A history chronic heart failure ( CHF ) IIIIV NewYork Heart Association ( NYHA ) ; 3 . Presence leave ventricular hypertrophy confirm echocardiography ; 4 . QRS complex exceed 1.0 ; 5 . Ejection fraction le 40 % ; 6 . Presence hemodynamically relevant stenosis exceed 30 % several coronary artery confirm CAG ; 7 . Type 1 diabetes mellitus ; 8 . Type 2 diabetes mellitus require pharmacotherapeutic correction insulin ; 9 . Any severe concurrent disease ; 10 . A history acute cerebrovascular accident ( ACVA ) within 6 month period precede study ; 11 . Active hepatic disease liver enzyme elevation unclear etiology 3 time high upper limit normal ; 12 . Hepatic failure bilirubin elevation 1.5 time high upper limit normal ; 13 . Uncontrolled arterial hypertension ( AH ) , systolic blood pressure ( SBP ) exceed 180 mm Hg diastolic blood pressure ( DBP ) exceed 110 mm Hg ; 14 . A history heart rhythm and/or cardiac conduction disorder ; 15 . Inborn and/or acquire heart defect ; 16 . A history aortic aneurysm ; 17 . Current existence severe anemia ( Hb &lt; 100 g/L ) ; 18 . Chronic renal disease ( creatinine clearance &lt; 30 mL/min ) ; 19 . Uncorrected thyroid dysfunction , hyper hypothyroidism ; 20 . Intolerance statin ; 21 . Alcohol abuse drug use ; 22 . Participation clinical study within last two month .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>STEMI</keyword>
	<keyword>myocardial strain</keyword>
	<keyword>atorvastatin</keyword>
</DOC>